Bristol-myers Squibb Compnay

Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Innate Tumor Immunity, Inc.

Andrew Forrest Donnell

Yong Zhang

Yan Lou

Robert Michael Borzilleri

Stacy W Remiszewski

Robert Francis Kester

Andrew J Tebben

Kang Le

Christophe Michoud

Gretchen M Schroeder

Donna Wei

Heidi L Perez

Erik M Stang

Kenneth Carey Rupert

Shomir Ghosh

Ashvinikumar V Gavai

Kyoung S Kim

Brian E Fink

William R Roush

Steven P Seitz

Prasanna Sivaprakasam

Yufen Zhao

Jay A Markwalder

Norman Kong

Weiya Yun

Shaoqing Chen

Liping Zhang

Muthoni G Kamau

Xiaochun Han

John Anthony Moliterni

Martin Weisel

John Anthony

The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

NLRP3 modulators

Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R, R, R, Rand Rare as described in this application, and methods of using said compounds in the treatment of cancer. 

Tetrahydro-benzodiazepinones

Macrocyclic benzodiazepine dimers having a structure represented by formula I where A and B are independently according to formulae Ia or Ib and the other variables in formulae I, Ia, and Ib are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used as the drug component in an antibody-drug conjugate (ADC).

Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses

The invention relates generally to compounds that modulate the activity of TGF&#x3b2;R-1 and TGF&#x3b2;R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

TGF&#x3b2;R antagonists

Disclosed are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein W, Y, Z, R1, R2, R3, R4 and R5 are described herein, and methods of using said compounds in the treatment of cancer. 

2-oxo-2,3,4,5-tetrahydro-1 H-benzo[B]diazepines and their use in the treatment of cancer

There are provided compounds of the formula 

Substituted hetero-azepinones

Growing community of inventors

West Windsor, NJ, United States of America

Andrew Forrest Donnell